首页> 外国专利> METHODS FOR PREDICTING MULTIPLE MYELOMA TREATMENT RESPONSE

METHODS FOR PREDICTING MULTIPLE MYELOMA TREATMENT RESPONSE

机译:预测多发性骨髓瘤治疗反应的方法

摘要

The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein i represent the regression coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASR v) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASR or concluding that the patient will not respond to the HDACi when the HAS score is lower than the predeference value HASR HAS = i = 1 n     i × Ci ( I )
机译:本发明涉及一种测试患有骨髓瘤的患者是否会对组蛋白脱乙酰基酶抑制剂(HDACi)反应的方法,该方法包括:确定生物学样品中选自表A的几种基因G1-Gn的表达水平(ELi)。从所述患者获得,将步骤i)中确定的表达水平(ELi)与预定参考水平(ELRi)进行比较; iii)通过以下公式计算HAS分数,其中i代表基因Gi和Ci = 1的回归系数参考值如果基因Gi(ELi)的表达高于预定参考水平(ELRi),或者Ci = 1;如果基因(ELi)的表达低于或等于预定参考水平(ELRi),则比较得分HAS在步骤iii)中确定为具有预定参考值HASR v),并得出结论,当HAS得分高于预定参考值HASR或结论为tha时,患者将对HDACi做出反应t当HAS评分低于预先设定的值时,患者将不会对HDACi做出反应HASR HAS = i = 1 n i×Ci(I)

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号